Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2002 Nov 9;325(7372):1070.
doi: 10.1136/bmj.325.7372.1070.

Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data

Sean Hennessy  1 , Warren B Bilker, Jill S Knauss, David J Margolis, Stephen E Kimmel, Robert F Reynolds, Dale B Glasser, Mary F Morrison, Brian L Strom
Affiliations

Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data

Sean Hennessy et al. BMJ. .

Abstract

Objective: To examine the rates of cardiac arrest and ventricular arrhythmia in patients with treated schizophrenia and in non-schizophrenic controls.

Design: Cohort study of outpatients using administrative data.

Setting: 3 US Medicaid programmes.

Participants: Patients with schizophrenia treated with clozapine, haloperidol, risperidone, or thioridazine; a control group of patients with glaucoma; and a control group of patients with psoriasis.

Main outcome measure: Diagnosis of cardiac arrest or ventricular arrhythmia.

Results: Patients with treated schizophrenia had higher rates of cardiac arrest and ventricular arrhythmia than controls, with rate ratios ranging from 1.7 to 3.2. Overall, thioridazine was not associated with an increased risk compared with haloperidol (rate ratio 0.9, 95% confidence interval 0.7 to 1.2). However, thioridazine showed an increased risk of events at doses > or =600 mg (2.6, 1.0 to 6.6; P=0.049) and a linear dose-response relation (P=0.038).

Conclusions: The increased risk of cardiac arrest and ventricular arrhythmia in patients with treated schizophrenia could be due to the disease or its treatment. Overall, the risk with thioridazine was no worse than that with haloperidol. Thioridazine may, however, have a higher risk at high doses, although this finding could be due to chance. To reduce cardiac risk, thioridazine should be prescribed at the lowest dose needed to obtain an optimal therapeutic effect.

PubMed Disclaimer

Figures

Figure
Figure
Algorithm for identifying potential death
See this image and copyright information in PMC

References

    1. Zarate CA, Jr, Patel J. Sudden cardiac death and antipsychotic drugs: do we know enough? Arch Gen Psychiatry. 2001;58:1168–1171. - PubMed
    1. Committee for Proprietary Medicinal Products of the European Agency for the Evaluation of Medicinal Products. Points to consider: the assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. 12-17-1997. London: Committee for Propriety Medicinal Products of EAEMP; 1997. www.emea.eu.int/pdfs/human/swp/098696en.pdf (accessed 16 October 2002).
    1. Cavero I, Mestre M, Guillon JM, Crumb W. Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias. Exp Opin Pharmacother. 2000;1:947–973. - PubMed
    1. De Ponti F, Poluzzi E, Montanaro N. QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience. Eur J Clin Pharmacol. 2000;56:1–18. - PubMed
    1. De Ponti F, Poluzzi E, Montanaro N. Organising evidence on QT prolongation and occurrence of torsades de pointes with non-antiarrhythmic drugs: a call for consensus. Eur J Clin Pharmacol. 2001;57:185–209. - PubMed

Publication types